New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors

Head and neck squamous cell carcinoma (HNSCC) is a relatively rare cancer that worldwide affects approximately 600,000 patients [1]. In England, depending on primary site, the HNSCC incidence varies from 3.01 per 100,000 habitants for laryngeal cancer to 3.02 for oral cancer [2].

http://ift.tt/2mnvDHk